Sheeja T Pullarkat from 3809 Chevy Chase Dr, La Canada, CA 91011, age 57, Phone: (818)9526235

Resumes

Clinical Associate Professor

view source

Work:

David Geffen School of Medicine at Ucla
Clinical Associate Professor

Medicine Doctors

Dr. Sheeja Pullarkat, Los Angeles CA - MD (Doctor of Medicine)

view source

Specialties:

Hematology
Hematopathology

Address:

Department Ophthalmology
10833 Le Conte Ave Suite B-186, Los Angeles, CA 90095
(310)7948285 (Phone)

UCLA Medical Center
10833 Le Conte Ave Suite B-186C, Los Angeles, CA 90095
(310)7947953 (Phone)

UNIVERSITY OF CALIFORNIA LOS ANGELES JONSSON CANCER CENTER
10833 Le Conte Ave, Los Angeles, CA 90095
(310)8256761 (Phone), (310)2067837 (Fax)

Certifications:

Anatomic & Clinical Pathology, 2005
Hematology & Pathology, 2006

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Calicut Medical College
Medical School
Usc/ Kenneth Norris Cancer Hospital

Sheeja T. Pullarkat

view source

Specialties:

Clinical Pathology

Work:

UCLA Pathology Outreach
10833 Le Conte Ave BLDG CHS, Los Angeles, CA 90095
(310)2672680 (phone), (310)2672685 (fax)

Education:

Medical School
Med Coll, Calicut Univ, Calicut, Kerala, India
Graduated: 1994

Languages:

English

Description:

Dr. Pullarkat graduated from the Med Coll, Calicut Univ, Calicut, Kerala, India in 1994. She works in Los Angeles, CA and specializes in Clinical Pathology. Dr. Pullarkat is affiliated with Harbor UCLA Medical Center.

Sheeja Thankappan Pullarkat, Los Angeles CA

view source

Specialties:

Anatomic Pathology & Clinical Pathology
Hematology
Anatomic Pathology
Clinical Pathology/Laboratory Medicine

Work:

University of California at Los Angeles
10833 Le Conte Ave, Los Angeles, CA 90095
Ronald Reagan Ucla Medical Center
757 Westwood Plz, Los Angeles, CA 90095

Education:

Calicut University Medical College - Kerala (1994)

Sheeja Thankappan Pullarkat, Los Angeles CA

view source

Specialties:

Pathologist

Address:

10833 Le Conte Ave, Los Angeles, CA 90095

Education:

Calicut Medical College - Bachelor of Medicine, Bachelor of Surgery

Board certifications:

American Board of Pathology Certification in Clinical Pathology (Pathology)
American Board of Pathology Sub-certificate in Hematology (Pathology)

Name / Title

Company / Classification

Phones & Addresses

Sheeja T. Pullarkat
Clinical Pathology

U C L A Orthopedic Associates
Medical Doctor's Office

10833 Le Conte Ave, Los Angeles, CA 90095

Sheeja Pullarkat
Medical Doctor

Ucla Medical Center Auxiliary
Social Services

10833 Le Conte Ave, Los Angeles, CA 90095
(310)3256003

Sheeja T. Pullarkat
Medical Doctor

University of California, Los Angeles
College/University Administrative Educational Programs

Ctr For Health Scienc, Los Angeles, CA 90095
(310)8257354

Sheeja Pullarkat
Clinical Pathology

U C L A Medical Group
Medical Doctor's Office · Offices and Clinics of Medical Doctors

10833 Le Conte Ave, Los Angeles, CA 90095
(310)8259111, (310)8257882

Sheeja Pullarkat
Clinical Pathology

Ucla Health System
Medical Doctor's Office · Offices and Clinics of Medical Doctors, Nsk

757 Westwood Plz, Los Angeles, CA 90095

Sheeja Pullarkat
Clinical Pathology

Nuclear Medicine
Medical Doctor's Office

10833 Le Conte Ave, Los Angeles, CA 90095
200 Medical Plz, Los Angeles, CA 90095
(310)7942101

Us Patents

Genomic Polymorphism For Predicting Therapeutic Response
view source
US Patent:

20120129178, May 24, 2012
Filed:

Jun 3, 2011
Appl. No.:

13/153233
Inventors:

Heinz-Josef Lenz - Altadena CA, US
Sheeja Thankappan Pullarkat - Glendale CA, US
Yi Ping Xiong - Alhambra CA, US
International Classification:

C12Q 1/68
G01N 27/447
US Classification:

435 612, 435 613, 204450
Abstract:

The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU.

Genomic Polymorphism For Predicting Therapeutic Response
view source
US Patent:

20080286789, Nov 20, 2008
Filed:

Apr 25, 2008
Appl. No.:

12/110044
Inventors:

Heinz-Josef Lenz - Altadena CA, US
Sheeja Thankappan Pullarkat - Glendale CA, US
Yi Ping Xiong - Alhambra CA, US
International Classification:

C12Q 1/68
US Classification:

435 6
Abstract:

The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU.